ClinConnect ClinConnect Logo
Search / Trial NCT01575223

Saline Irrigation After Surgery in Patients With Chronic Sinusitis

Launched by SAMUEL LUNENFELD RESEARCH INSTITUTE, MOUNT SINAI HOSPITAL · Apr 9, 2012

Trial Information

Current as of May 18, 2025

Completed

Keywords

Saline Irrigation Chronic Rhinosinusitis Endoscopic Sinus Surgery High Volume Saline Irrigation

ClinConnect Summary

Background: Chronic Rhinosinusitis (CRS) is a common inflammatory condition of the upper respiratory tract lasting more than 8 to 12 weeks. Major symptoms include facial congestion/fullness, facial pain/pressure, nasal obstruction/blockage, purulent nasal drainage, and reduction or loss of smell. The diagnosis must include two major symptoms and either endoscopic evidence of polyps, edema or mucopurulent discharge from the middle meatus and/or CT changes in the mucosa of sinuses or osteomeatal complexes.1

CRS has an estimated prevalence of 5% in the Canadian population2, and up to 16% in s...

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • Documented diagnosis of unilateral or bilateral CRS
  • Documented failed medical treatment of CRS
  • Eighteen (18) to sixty-five (65) years of age
  • Planned ESS for the treatment of CRS
  • Able to read and understand English
  • Exclusion criteria:
  • Pregnant
  • Cystic Fibrosis
  • Diagnosed immotile cilia syndrome
  • Diagnosed immunodeficiency syndrome
  • Diagnosed fungal sinusitis
  • Sinonasal tumours or obstructive lesions

About Samuel Lunenfeld Research Institute, Mount Sinai Hospital

The Samuel Lunenfeld Research Institute at Mount Sinai Hospital is a leading biomedical research facility dedicated to advancing our understanding of human health and disease. Renowned for its innovative research programs, the institute focuses on areas such as cancer, genetics, and reproductive health, fostering collaboration among top-tier scientists and clinicians. With a commitment to translating research findings into clinical applications, the Samuel Lunenfeld Research Institute plays a pivotal role in the development of novel therapies and interventions, thereby contributing to improved patient outcomes and the advancement of medical science.

Locations

Calgary, Alberta, Canada

London, Ontario, Canada

Ottawa, Ontario, Canada

Toronto, Ontario, Canada

Patients applied

0 patients applied

Trial Officials

Ian J Witterick, MD MSc FRCSC

Principal Investigator

Samuel R Lunenfeld Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials